Objective-We evaluated the biological effects of low-dose methotrexate on 3 novel brachial artery grayscale ultrasound measures that may indicate subclinical arterial injury. Approach and Results-Exploratory analysis from a clinical trial of people with HIV infection at increased cardiovascular disease risk who were randomly assigned to low-dose methotrexate (target dose 15 mg/wk) or placebo. Brachial artery ultrasound grayscale median, gray level difference statistic texture-contrast (GLDS-CON), and gray level texture entropy were measured at baseline and after 24 weeks of intervention. Findings from the intention-to-treat (N=148) and adequately-dosed (N=118) populations were consistent, so the adequately-dosed population results are presented. Participants were a median (Q1, Q3) age of 54 (50, 60) years. After 24 weeks, the low-dose methotrexate intervention was associated with a 25.4% (−18.1, 58.6; P=0.007) increase in GLDS-CON compared with 1.3% (−29.1, 44.7; P=0.97) with placebo (P=0.05) and a 0.10 u (−0.06, 0.23; P=0.026) increase in entropy compared with 0.02 u (−0.11, 0.14; P=0.54) with placebo (P=0.14). At week 24, changes in CD4+ T cells correlated inversely with changes in GLDS-CON (ρ=−0.20; P=0.031), and entropy (ρ=−0.21; P=0.023). Changes in D-dimer levels, but no other inflammatory biomarkers, also correlated inversely with changes in GLDS-CON (ρ=−0.23; P=0.014) and entropy (ρ=−0.26; P=0.005). Conclusions-Brachial artery GLDS-CON and entropy increased after 24 weeks of low-dose methotrexate, though the latter was not significantly different from placebo. Grayscale changes were associated with decreases in CD4+ 
xcess atherosclerotic cardiovascular disease (ASCVD) risk in people with HIV infection may be related to inflammation and disordered immune regulation that persist despite suppression of viral replication. [1] [2] [3] [4] [5] [6] [7] Traditional techniques for imaging arterial injury in HIV have been limited to those that detect macroscopic changes such as carotid artery wall thickening, coronary artery calcification, carotid and coronary artery plaque formation, and brachial artery (BA) flow-mediated dilation. 8 The conclusions of studies that used these imaging technologies generally agreed with epidemiological observations that HIV infection is associated with increased ASCVD risk in addition to traditional ASCVD risk factors; however, the effects of antiretroviral and anti-inflammatory therapies on ASCVD risk and arterial injury are not known. [1] [2] [3] [4] [8] [9] [10] Studies using 11 F-fluorodeoxyglucose positron emission tomography/ computed tomography imaging identified persistent arterial inflammation among treated and suppressed patients with HIV infection, which correlates with circulating inflammatory markers. 5, 12, 13 In AIDS Clinical Trials Group Study A5314, anti-inflammatory treatment with low-dose methotrexate (LDMTX) did not improve BA endothelial function or 8 inflammatory biomarkers in people with treated and suppressed HIV infection.characterize tissue composition in the carotid arterial wall and in plaques. First-order statistics, such as the grayscale median (GSM) and entropy are derived from the image pixel brightness histogram and can be used to characterize the overall echogenicity and randomness in the arterial wall. 16, 17, 20, 21 Gray level difference statistics, such as contrast (GLDS-CON), describe spatial relationships between 2 ultrasound pixels. 16, 17, 20, 21 When measured in the carotid arterial bed, these parameters have been associated with ASCVD risk factors and future ASCVD events. 11, 19, [21] [22] [23] [24] [25] [26] Carotid artery GSM levels have been associated with ASCVD risk factors in HIV-infected women 26 and with circulating levels of inflammatory and oxidation biomarkers in older adults. 23 Changes in carotid artery GSM have been described with statin therapy in the general population [27] [28] [29] ; however, little is known about these markers in the BA other than 1 cross-sectional study of ASCVD risk factors in older adults. 30 They have not been studied in people living with HIV infection, and their response to an anti-inflammatory intervention has never been assessed previously.
We performed an exploratory analysis to evaluate the biological effects of LDMTX on 3 novel BA grayscale ultrasound measures that may indicate subclinical arterial injury: BA GSM, entropy, and GLDS-CON. We also performed ultrasound phantom imaging to demonstrate the effects of ultrasound scatterer properties on these grayscale ultrasound measures.
Materials and Methods
Data, analytic methods, and study material are accessible by the public and other investigators using standard operating procedures from the National Institute of Health's AIDS Clinical Trials Group (https://actgnetwork.org/clinical-trials/access-published-data).
Participants
The analysis population was comprised of participants in A5314 (http://www.clinicaltrials.gov. Unique identifier: NCT01949116), a phase II, randomized, multicenter, double-blind, placebo-controlled trial that evaluated the safety and efficacy of LDMTX among HIVinfected individuals at least 40 years old who had been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks, who had a CD4+ T-cell count ≥400 cells/mm 3 , and who had documented ASCVD, or who were at increased ASCVD risk. 14 Participants started on 5 mg weekly of LDMTX or placebo at study entry, and if tolerated after 1 week, the dose was increased to 10 mg weekly through week 12, then if tolerated, the dose was increased to 15 mg weekly until week 24. Folic acid, 1 mg daily, was prescribed to participants in both study groups. All participants provided informed consent, and the study was approved of by the institutional review boards at each participating site and the Brachial Artery Ultrasound Reading Center in Madison, WI. The study design, biomarker measurement techniques, and main outcomes were presented previously.
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BA Ultrasound Imaging and Measurement of Flow and Diameters
Participants were required to fast, not smoke, not drink caffeinated products, or exercise for at least 8 hours before testing.
14,31-34 Using a linear array vascular ultrasound transducer, the right BA was located above the elbow and scanned in longitudinal sections. After recording resting B-mode images of the BA and spectral Doppler images of flow, the forearm cuff was inflated to 250 mm Hg for 5 minutes to induce reactive hyperemia. Immediately after cuff deflation, spectral Doppler images were obtained to verify hyperemia and to determine peak BA hyperemic flow velocity. All images were acquired by sonographers who were trained and certified by University of Wisconsin Atherosclerosis Imaging Research Program Laboratory. BA ultrasound images were sent electronically to the core lab for quality assessment and interpretation by a single, experienced technician using Access Point Web software (Freeland Systems, Alpharetta, GA). BA diameters and spectral Doppler flow velocities were measured in triplicate before and after reactive hyperemia at both time points. Flow-mediated dilation was defined as the ratio of the maximum BA diameter obtained within 90 s after reactive hyperemia to the resting diameter, expressed as a percent.
BA Grayscale Analysis
Resting Digital Imaging and Communications in Medicine images of the proximal BA at end diastole were converted to bitmaps and normalized by assigning the blackest area of the blood a grayscale value of 0 and the whitest area of the middle two-fourths of the adventitia a grayscale value of 190, then were standardized to a uniform pixel density of 20/mm using LifeQ Medical Software (Nicosia, Cyprus; Figure 1) . 24, 25, 31, 35 A reproducible 10 mm segment of the BA wall that was present in all scans within and between visits was segmented by placing the caliper on the blood-intima and media-adventitia interfaces. From this segmentation process, first-order statistics from the image histogram were used to measure GSM (a measure of overall echogenicity of the pixels in the BA far wall) and entropy (a measure of randomness of the pixels in the BA far wall). The gray level difference statistic method was used to measure contrast (a measure of differences in grayscale values between pixels at different distances and directions in the BA far wall). 25, 31 Each grayscale measure is in arbitrary units.
Ultrasound Phantom Studies
We acquired images from 2 unique ultrasound phantoms with different acoustic scattering properties ( Figure 2 ). One phantom was custom built at the University of Wisconsin (Clear 800 July 29, 1999) 36 with 800 glass bead scatterers/cm 3 , sound speed of 1542 m/s at 22°C) and 1 phantom is commercially available (404GS precision small parts grayscale phantom with tissue-mimicking material at speed of sound 1540±10 m/s and attenuation coefficient 0.7±0.01 dB/cm-MHz, Gammex, Middleton, WI). Images were acquired using the same ultrasound system, transducer, and instrumentation settings (Acuson S2000 ultrasound system, 9L4 transducer; Siemens Medical Solutions, Malvern, PA).
Statistical Analysis
Between-intervention group comparisons used the Wilcoxon ranksum test or Fisher exact test. Within-group changes in continuous outcomes used the Wilcoxon signed-rank test. Correlations were assessed with the nonparametric Spearman correlation coefficient (ρ) and its associated P value. All P values are presented at their nominal alpha level of 0.05 with no formal adjustment for multiple comparisons. Because of site differences in ultrasound instrumentation, we performed sensitivity analyses using mixed effects models for changes in GSM, GLDS-CON, and entropy that included main intervention and random side effects. Analyses also were performed on the log 10 scale to represent relative rather than absolute effects of the intervention. Scan-rescan and measurement agreement between paired baseline measures were summarized by Bland-Altman plots and intraclass correlation coefficients. Because Bland-Altman plots revealed a cone-shape with increasing differences between values at higher values of GLDS-CON that were not seen with log 10 transformation, these measurement values were analyzed on the log 10 scale and backtransformed to percentage change values for presentation.
Findings from the intention-to-treat (N=176 participants randomized to study A5314, 148 with readable images at weeks 0 and 24) and adequately-dosed (N=129 with continuous 24-week including ≥8 15 mg doses of LDMTX or placebo, 118 with readable images at weeks 0 and 24) populations were consistent. Because the primary goal of this exploratory analysis was to evaluate the biological effects of LDMTX, results from the adequately-dosed population that would provide the maximum possible effect of the intervention 
Results

Participant Characteristics and Correlations at Baseline, Week 0
Participants were 94% male, had a median (Q1-Q3) age of 54 (50-60) years, and a 10-year ASCVD risk of 8.7% (5.1%-12.9%; Table 1 ). Corresponding values for the intention-totreat group participants are in Table I in Table 2 ). Similar correlations were not seen for GSM.
Changes in Grayscale Markers Within-and Between-Groups From Week 0 to 24
After 24 weeks, GSM did not change within-or betweengroups; however, the LDMTX intervention was associated with a 25.4% (−18.1%, 58.6%; P=0.007) increase in GLDS-CON compared with 1.3% (−29.1%, 44.7%; P=0.97) with placebo (between-group P=0.05) and a 0.10 units (−0.06, 0.23; P=0.026) increase in entropy compared with 0.02 units (−0.11, 0.14; P=0.54) with placebo (between-group P=0.14; Table 3 ). The within-group and between-arm differences for GLDS-CON and the within-group changes for entropy were robust in sensitivity analyses that included site adjustment and log 10 transformation. Corresponding values for the intention-to-treat analysis are in Table II in the online-only Data Supplement.
At week 24, changes in CD4+ T cells correlated inversely with changes in GLDS-CON (ρ=−0.20; P=0.031) and entropy (ρ=−0.21; P=0.023); directionally similar but not statically significant changes were noted for CD8+ T cells (Table 2) and for CD4+ and CD8+ T cells in analyses restricted to the LDMTX arm alone (data not shown). Changes in D-dimer levels correlated inversely with changes in GLDS-CON (ρ=−0.23; P=0.014), and entropy (ρ=−0.26; P=0.005). These correlations were similar in site-adjusted sensitivity analyses (data not shown). We did not find strong correlations between changes in any grayscale measure and changes in CRP, IL-6 (interleukin-6), or several other inflammatory biomarkers (ie, fibrinogen, interferon-γinducible protein-10, vascular cell adhesion molecule, soluble CD14, and soluble CD163; data not shown). We did not find any associations between changes in flow-mediated dilation and changes in any BA grayscale measure (data not shown)
Ultrasound Phantom Measurements
The ultrasound phantom with scatterer properties sufficient to produce a fully developed speckle pattern yielded images with a higher GSM value of 37.42 units, lower GLDS-CON value of 8.04 units, and lower entropy value of 3.25 units compared with a phantom constructed with 800 glass bead scatterers/ cm 3 that had a GSM value of 19.85 units, a GLDS-CON value of 114.79 units, and an entropy value of 4.21 units (Figure 2 ).
Grayscale Measurement Reproducibility
A single reader (J.M. Weber) measured images from 115 participants who were scanned twice at baseline, blinded to the first measurement. Intraclass correlation coefficients were 0.77 for GSM, 0.79 for GLDS-CON, and 0.69 for entropy.
Discussion
In this exploratory study of people with treated and suppressed HIV infection at increased ASCVD risk, 2 novel measures of BA grayscale texture-GLDS-CON and entropy-increased after 24 weeks of LDMTX, though the latter was not significantly different from placebo. These measures have not been described previously in the BA, though in the carotid artery, higher levels are associated with lower ASCVD risk and lower levels of ASCVD risk factors. 21, 25 Increases in all 3 grayscale markers correlated with reductions in CD4+ and CD8+ T cells, as well as D-Dimer, a marker of inflammation and coagulation that is associated with increased ASCVD risk and mortality in people with HIV 3, 37 and the general population. 38, 39 These findings may indicate that the grayscale changes observed in the LDMTX are related to less arterial inflammation.
There were no significant correlations between changes in grayscale markers and CRP, IL-6, or other inflammatory markers, in the primary analysis of study A5314. We also did not detect an effect of LDMTX on any of the 8 inflammatory biomarkers we measured, despite seeing significant declines in CD4+ and CD8+ T-cell subsets after 26 weeks. 14, 40, 41 We think this was because of the high variability in the levels of each inflammatory marker and that the T-cell count changes more reliably reflect the anti-inflammatory effects of LDMTX in this population. Interestingly, inflammatory markers that predict CVD risk in the general population (like hsCRP [high-sensitivity C-reactive protein] and IL-6) do not reliably predict CVD risk in HIV-infected populations 42 and when they do, their predictive power is less possibly owing to variation because of inflammation from persistent viremia, microbial translocation across the intestinal wall, infections, or immune activation because of HIV. 7 It is not a surprise that in a smaller study like ours that we did not see an effect of LDMTX on inflammatory biomarkers, especially in the presence of declines in CD4+ and CD8+ T-cell counts and numerically more infections, which likely overwhelmed LDMX effects on these variable biomarkers. 14, 40, 41 Atherosclerosis is common in the BA. 43 BA ultrasound imaging primarily has been used to study conduit artery endothelial function because BA flow-mediated dilation predicts future ASCVD events [44] [45] [46] [47] and improves with lipid-lowering therapy and antiretroviral therapy in people with HIV infection. 32, 48, 49 BA intima-media thickness also is related to ASCVD risk, 30, 50 but to our knowledge, there only has been 1 report that described associations of BA GSM, 30 and none has evaluated the other gray scale texture markers in the BA that we reported here. In a study of 1016 older adults in Sweden, BA GSM was associated with several ASCVD risk factors and independently associated with 2 measures of oxidation and inflammatory stress (conjugated dienes of low-density lipoproteins and oxidized glutathione). 30 We found that BA GSM was associated inversely with 2 inflammatory markers, CRP and D-Dimer, at baseline and that decreases in D-Dimer levels in the LDMTX group were associated with increases in BA GSM, GLDS-CON, and entropy. We also found associations of baseline levels of CD4+ and CD8+ T cells with baseline GLDS-CON and entropy, as well as associations between their changes with LDMTX. These findings may indicate that BA grayscale measures reflect arterial injury because of inflammation or T-cell changes.
Our ultrasound phantom experiments demonstrate that the BA grayscale measurements we reported differ based on the structure and scattering properties of the material that the ultrasound wave traverses. It is very likely that this is true with human tissue as well and that cellular changes in human tissue may lead to changes in their ultrasound scattering properties. Several studies that have examined ultrasound features of carotid plaques and histopathology from carotid endarterectomy specimens suggest that ultrasound grayscale features are strongly associated with tissue composition. 35 ,51,52 Echogenicity of the carotid artery wall and plaques change with statin treatment. [27] [28] [29] We recently demonstrated that improvements in walking function in people with peripheral artery disease were associated with increases in BA GLDS-CON and entropy; therefore, it is possible that the changes in grayscale texture features we observed in the LDMTX group represent changes in arterial wall composition associated with reduced arterial inflammation. 53 This is consistent with our previous report that LDMTX may be associated with less aortic uptake using 11 F-fluorodeoxyglucose positron emission tomography/computed tomography. 15 These exploratory data underscore the importance of newer imaging techniques like ultrasound grayscale analysis of arterial texture and 11 F-fluorodeoxyglucose positron emission tomography/computed tomography that may be able to detect arterial changes that are not evident in macroscopic measures of arterial size, thickness, or plaque burden. This study supports the value of advanced arterial ultrasound grayscale analyses to describe arterial pathophysiology and associations with clinical markers and interventions Although their clinical utility has not been established, we have demonstrated that in the carotid artery, higher GLDS-CON and entropy are associated with a significantly lower risk of coronary heart disease events in the MultiEthnic Study of Atherosclerosis. 21 To put our findings in context, we estimated the potential clinical effect size of the changes in GLDS-CON and entropy we observed, assuming that (1) the signal related to GLDS-CON is similar in the carotid arteries and the brachial arteries, (2) the longitudinal change in response to a drug intervention is similar to the cross-sectional effect size for predicting future coronary heart disease events, and (3) that mean population changes reflect individual risk responses. Given the magnitude of the increase in BA GLDS-CON we observed in the LDMTX group (+25.4%) from a baseline of 126 units, we expect this increase may be associated with an ≈ 5% to 14% decrease in risk of future coronary heart disease events.
Limitations
Although we described novel findings from a carefully conducted randomized clinical trial of a novel anti-inflammatory intervention in people with stable HIV disease, our findings have limitations. The BA grayscale measures we reported were from exploratory analyses that were not prespecified at the trial outset, so our findings should be considered hypothesis-generating with implications for BA imaging as a research tool and the effects of LDMTX on the BA, rather than its clinical effects. The BA markers explored in this study are highly novel, so the clinical relevance of their associations and changes we observed with LDMTX are uncertain; however, they provide insights into the pathobiology of arterial injury in stable HIV disease and changes with an anti-inflammatory intervention that appears to reduce ASCVD event risk in patients with autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis. [54] [55] [56] [57] Because the aim of this study was to investigate the biological effects of LDMTX on the BA (as opposed to its effect as a clinical intervention), we chose to report the adequately-dosed group results; however, the intention-to-treat results were very similar and are presented in the Tables in the online-only Data Supplement. Differences in ultrasound instrumentation at each site may have introduced variability into our measures; however, our findings were consistent in 2 sensitivity analyses, one using a mixed-model that controlled for the site effect and another that evaluated relative changes on a participant level. Though both GLDS-CON and entropy improved significantly in the LDMTX group, the 24-week change in entropy with LDMTX compared with the change in the placebo group was not statistically significant. Similarly, some of the correlations of changes in CD4+ and CD8+ T cells with changes in the gray scale markers after 24 weeks exceeded the nominal level of statistical significance, whereas others were just above it. It is possible that some of our findings may be because of chance given, the relatively small size of this study, and that some P values are close to 0.05; however, we think that the consistency of the findings in this study (especially in regard to the CD4+ T-cell and D-Dimer associations) and between studies provides insights into the pathobiology of arterial injury in stable HIV disease, changes with an anti-inflammatory intervention, as well as the potential use of ultrasound grayscale imaging of the BA as a research tool for investigating arterial biology and possibly cardiovascular disease risk. The modest, inverse baseline association of our measures with BA flowmediated dilation are difficult to explain, especially because BA flow-mediated dilation did not change with LDMTX in A5314, and changes in flow-mediated dilation were not associated with changes in the gray scale measures.
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Conclusions
In a post hoc analysis of data from a randomized clinical trial of people with HIV infection, BA GLDS-CON and entropy increased after 24 weeks of LDMTX, though the latter was not significantly different from placebo. Arterial texture changes were associated with decreases in CD4+ T cells and D-dimer levels and may indicate favorable changes in arterial structure. Advanced arterial ultrasound grayscale analysis is a promising tool to describe arterial pathophysiology and associations with clinical markers and interventions.
